News List
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
2019-07-12
Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib)
New drug delivery method, FDA approved a new epilepsy treatment
2019-06-29
UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment o
Holiday Notice of Dragon Boat Festival
2019-06-01
To all departments and employees:According to the related national legal & the actual situation
Long-term anti-AIDS, Combination of two schemes submits application
2019-05-29
On April 29, 2019,the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA
For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy
2019-04-27
Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolute
Novartis‘s Multiple sclerosis Innovative drug approved
2019-03-29
Recently, US FDA announced approved the listing of Mayzent (siponimod) developed by Novartis, for th
Highly efficient trifluoromethylation and [18F]trifluoromethylation
2019-03-02
Jichang Xiao, researcher at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, ha
Redox neutral [4+1] cyclic reaction based on C-F fracture
2019-01-19
Recently, Professor Feng Chao of the Institute of Advanced Synthesis of Nanjing University of Techno
FDA accelerates approval of no-limit cancer targeting therapy for the treatment of NTRK fusion tumors
2018-12-15
Recently, LOXO Oncology and Bayer jointly announced that the FDA has accelerated the approval of a c
FDA approves new mechanism for listing new anti-influenza drugs
2018-11-17
Today, the US FDA announced the approval of the new anti-influenza drug Xofluza (baloxavir marboxil)